Identification of proteomic biomarkers associated with eplerenone treatment versus spironolactone in post-acute coronary syndrome patients, with non-controlled arterial hypertension and ventricular dysfunction [Evaluacion mediante proteomica de biomarcadores proteicos asociados con el tratamiento con Eplerenona versus espironolactona en pacientes post-infarto agudo de miocardio, diabeticos con hipertension arterial no controlada y disfuncion ventricular sistolica leve]

Trial Profile

Identification of proteomic biomarkers associated with eplerenone treatment versus spironolactone in post-acute coronary syndrome patients, with non-controlled arterial hypertension and ventricular dysfunction [Evaluacion mediante proteomica de biomarcadores proteicos asociados con el tratamiento con Eplerenona versus espironolactona en pacientes post-infarto agudo de miocardio, diabeticos con hipertension arterial no controlada y disfuncion ventricular sistolica leve]

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2011

At a glance

  • Drugs Eplerenone; Spironolactone
  • Indications Heart failure; Hypertension; Ventricular dysfunction
  • Focus Biomarker; Pharmacodynamics
  • Acronyms PROMETEO
  • Most Recent Events

    • 12 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top